TAK logo

TAK
Takeda Pharmaceutical Co Ltd (ADR)

3,706
Mkt Cap
$52.7B
Volume
437,538.00
52W High
$18.90
52W Low
$12.99
PE Ratio
67.31
TAK Fundamentals
Price
$16.66
Prev Close
$16.68
Open
$16.60
50D MA
$17.94
Beta
0.26
Avg. Volume
2.81M
EPS (Annual)
$0.2242
P/B
1.08
Rev/Employee
$633,289.19
$79,201.26
Loading...
Loading...
News
all
press releases
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·1d ago
News Placeholder
More News
News Placeholder
China Universal Asset Management Co. Ltd. Takes Position in Takeda Pharmaceutical Co. $TAK
China Universal Asset Management Co. Ltd. bought a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent Form 13F filing...
MarketBeat·6d ago
News Placeholder
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.
Zacks·7d ago
News Placeholder
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.
Zacks·8d ago
News Placeholder
Takeda Pharmaceutical Enters Oversold Territory (TAK)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets·9d ago
News Placeholder
Will Asceniv Deliver for ADMA in the Upcoming Quarterly Results?
ADMA banks on surging Asceniv demand to sustain growth, supported by expanded plasma supply and broader coverage, which should drive continued gains into 2026.
Zacks·9d ago
News Placeholder
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.
Zacks·14d ago
News Placeholder
Does ADMA Biologics' Growth Story Outweigh Short-Seller Concerns?
ADMA stock slides after a short report sparks volatility, but management pushes back, citing strong Asceniv demand and steady fundamentals.
Zacks·15d ago
News Placeholder
ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?
ADMA stock plunges after a short report, but strong Asceniv demand, rising revenues, and margin expansion signal potential recovery ahead.
Zacks·16d ago
News Placeholder
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·17d ago
<
1
2
...
>

Latest TAK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.